上周政策端进一步体现出对创新医疗药械的支持力度，工业和信息化部、国家发展改革委、教育部、国 家卫生健康委、国务院国资委、中国科学院、国家药监局七部门发布《关于推动脑机接口产业创新发展 的实施意见》。国内将加强基础软硬件攻关，打造高性能产品，将在2027年和2030年分阶段展现出成 果。 永赢基金表示，脑机接口赛道应用场景多元化、产品及研发路径丰富，未来潜在空间巨大，在国内政策 加持下有望加速实现商业化普及。全球产品研发布局企业众多， 国内部分头部企业已经集中在非侵入 式领域产品取得多项技术突破，产品将迎来巨大的商业化潜力。 中证网讯 在创新医疗器械政策支持下，国产医疗器械企业出海持续加速。Wind数据显示，8月12日盘 中，全市场同类产品规模最大的医疗器械ETF（159883）涨超2%，资金申购超2亿份，近一周，该ETF 份额增长14.8亿份，连续5个交易日实现净申购。 消息面上，近日心脉医疗的Hercules®-LP直管型覆膜支架及输送系统在马来西亚成功完成首例临床植 入，标志着这款产品正式在该国进入临床应用，进一步丰富了心脉医疗在该市场的产品线布局。此前， 赛诺医疗发布子公司产品获美国FDA突破性医疗器械 ...

Core Viewpoint - The medical device and consumables sectors, along with AI healthcare, are experiencing significant growth driven by favorable policies and market dynamics. Group 1: Medical Device and Consumables Sector - The Hong Kong medical ETF (159366) saw a rise of over 4.5% on July 30, with a trading volume nearing 600 million, benefiting from the active market for innovative drugs and devices [1] - The medical device ETF (159883) recorded a net inflow of 2.03 billion, ranking first among comparable funds, with a total of 7.14 billion in net inflows over nine consecutive days [1] - Policy expectations are positive, with high-value consumables expected to benefit from improved procurement policies, leading to a reduction in valuation pressure and a more stable long-term performance outlook for leading companies [1][3] Group 2: Policy Support and Market Dynamics - Continuous policy support for the medical consumables sector is shifting the focus from price wars to value wars, with the National Medical Insurance Bureau facilitating the pricing of innovative medical consumables [3] - The optimization of the 11th batch of national drug procurement rules aims to address the issue of price undercutting, allowing companies to maintain profit margins and focus on innovation [3][4] - The simplification of the approval process for innovative consumables is expected to accelerate their market entry, enhancing the support for clinically valuable new products [4] Group 3: AI Healthcare Sector - The AI healthcare sector is gaining momentum, with the 2025 World Artificial Intelligence Conference showcasing practical applications that address clinical challenges and promote scalable solutions [5] - The release of the "2025 Artificial Intelligence + Health Shanghai Practice" outlines a development path for AI healthcare, focusing on data flow issues and the integration of AI with biomedicine [5] - The Hong Kong medical ETF (159366) has become a key investment vehicle for AI healthcare, reflecting a 7.36% increase over the past week, driven by the sector's growth potential [6] Group 4: Investment Trends and Market Sentiment - The release of policy benefits has positioned medical consumables and AI healthcare as core investment areas, with significant capital inflow observed in these sectors [6] - The recovery of domestic medical equipment procurement is expected to boost upstream consumable demand, while AI healthcare companies in Hong Kong are attracting foreign investment due to their technological advantages [6][7] - The collaboration between the recovery of the CXO sector and AI healthcare is amplifying growth potential, as domestic CXO companies leverage cost advantages to secure more AI-driven drug development contracts [7]

Core Viewpoint - The medical device sector is experiencing significant growth driven by the explosion in CXO, medical consumables, and AI medical segments, leading to a notable increase in the performance of related ETFs [1][2][3]. Group 1: ETF Performance - The medical device ETF (159883) opened high and rose by 0.96% during the early session, with a peak increase of nearly 2%, marking an attempt for an eight-day consecutive rise [1]. - As of July 24, the medical device ETF (159883) had a net subscription of 180 million shares in the early session, with a total circulation of 4.762 billion shares, reflecting an increase of nearly 1 billion shares over the past month [1]. - The latest circulation scale of the medical device ETF (159883) reached 2.466 billion yuan, making it the largest medical device ETF product among Wind industry ETFs [1]. Group 2: Policy and Market Dynamics - The Hong Kong medical ETF (159366) saw a rise of 2.08% in early trading, with an intraday peak exceeding 4%, indicating a potential three-day consecutive increase [2]. - The National Medical Insurance Administration recently held a seminar to discuss new measures for supporting innovative drugs and medical devices, including the establishment of new medical service pricing projects and encouraging the global development of Chinese innovative drugs and devices [2]. - The latest round of national drug procurement has started, with new rules being optimized to reduce reliance on minimum pricing, which is expected to alleviate competitive pressure in the high-value consumables sector [2][3]. Group 3: Sector Outlook - Analysts from Ping An Securities suggest that the high-value consumables sector may benefit from favorable policy expectations, with ongoing optimization of procurement policies expected to reduce valuation pressure [3]. - Huatai Securities indicates that the pressure from the US interest rate hike cycle on new drug financing is gradually easing, leading to a recovery in overseas new drug research and development demand, which is beneficial for Chinese companies [3]. - The medical device ETF (159883) tracks the CSI All-Index Medical Device Index, covering various sub-sectors such as medical equipment, consumables, and in vitro diagnostics, positioning it as a key player in the market [3].